Theravance Biopharma’s $100.5 Million Shares Offering

Davis Polk advised the underwriters in the offering.Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq Global…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here